TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07868419: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

Sponsor: Trevi Therapeutics · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 201 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07868419 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07868419 Rescue Dossier →